TORONTO, Sept. 9 /CNW/ - Alegro Health Corp. (TSX-V: AGO), a provider of
medical, surgical and disability management and clinical trial administration
services, today announced that CanAm Research Corp., a unit of Alegro's drug
trial management division, has entered into separate contracts for the
adminstration of two clinical drug research trials.
"We are extremely excited about our first two contracts for the CanAm
Research unit of our new drug trial management division," said Brenda
Rasmussen, President and Chief Executive Officer of Alegro Health Corp. "The
level of services offered through our drug trial management division will
enable us to continue to attract pharmaceutical, biotech and medical device
companies and take advantage of the growing number of clinical trials in
The contracts have been consumated with a major pharmaceutical company.
The tests are orthopaedic in nature and will initiaite enrollment by the end
of September 2008.
Due to privacy issues related to the management of pharmacological
clinical trials, Alegro is unable to publish specific details of either the
drugs in development or the precise terms of the contracts.
About Alegro Health Corp.
Alegro Health Corp. is a leading Canadian healthcare services provider
that offers medical and consulting services to corporations and individuals.
Through the company's subsidiaries - Don Mills Surgical Unit, Work Able
Centres, Direct Health Solutions and CanAm Research - Alegro provides a
variety of surgical procedures, disability management, third-party medical
assessments and support of drug trial administration. With a broad service
offering and the growth of the healthcare services sector, Alegro is pursuing
a vertically integrated approach and an aggressive acquisition strategy to
become Canada's leading third-party healthcare services provider. Alegro is
listed on the TSX Venture Exchange under the symbol AGO. For further
information, please visit www.alegrohealth.com.
Certain information in this press release is based on beliefs and
assumptions of the Company's senior management and information currently
available to it that may constitute forward-looking information within the
meaning of securities laws. Such statements reflect the current views of the
Company with respect to future events and are subject to certain risks and
uncertainties. Actual results, events, and performance may differ materially.
Readers are cautioned not to place undue reliance on these forward-looking
This release was prepared by management of the Company who takes full
responsibility for its contents. The TSX Venture Exchange has not
reviewed and does not accept responsibility for the adequacy or accuracy
of this news release.
For further information:
For further information: Brenda Rasmussen, President and CEO, (416)
496-6166 x-328, email@example.com; Michael Moore, Investor
Relations, (416) 815-0700 x241, firstname.lastname@example.org